Cell Biology Quiz: Pi3k Akt Mtor Signaling
20 questions · exam conditions
0:00
Pi3k Akt Mtor SignalingQuestion 1 of 20

A research team creates cells with a mutant AKT that cannot be phosphorylated at Ser473 but retains normal Thr308 phosphorylation. When these cells are treated with growth factors, which outcome would be most expected?

Complete loss of both growth and survival responses to growth factors
Normal growth responses but significantly impaired survival signaling
Enhanced mTORC1 activation due to loss of negative feedback
Increased sensitivity to apoptotic stimuli but normal glucose metabolism
Compensatory upregulation of mTORC2 activity to restore AKT function
← Back to quizzes

Cell Biology Quiz

Cell Biology Quiz: Pi3k Akt Mtor Signaling

Practice Pi3k Akt Mtor Signaling in Cell Biology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Pi3k Akt Mtor Signaling, giving you a quick way to practice the rules, question types, and explanations that matter most for Cell Biology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A research team creates cells with a mutant AKT that cannot be phosphorylated at Ser473 but retains normal Thr308 phosphorylation. When these cells are treated with growth factors, which outcome would be most expected?

  1. Complete loss of both growth and survival responses to growth factors
  2. Normal growth responses but significantly impaired survival signaling (correct answer)
  3. Enhanced mTORC1 activation due to loss of negative feedback
  4. Increased sensitivity to apoptotic stimuli but normal glucose metabolism
  5. Compensatory upregulation of mTORC2 activity to restore AKT function
Explanation: When you encounter questions about AKT phosphorylation, focus on understanding that AKT has two critical phosphorylation sites with distinct functions. Thr308 phosphorylation by PDK1 primarily drives metabolic responses and growth signaling, while Ser473 phosphorylation by mTORC2 is essential for maximal AKT activation and survival signaling. In this mutant scenario, cells retain Thr308 phosphorylation but lose Ser473 phosphorylation. This means AKT can still partially activate downstream pathways involved in glucose metabolism and protein synthesis (growth responses), but it cannot achieve full activation needed for robust anti-apoptotic signaling. The dual phosphorylation requirement means that without Ser473, AKT's ability to phosphorylate key survival targets like BAD and FoxO transcription factors is significantly compromised. Answer B correctly identifies this partial loss of function - normal growth responses persist through Thr308-dependent pathways, but survival signaling is impaired due to insufficient overall AKT activity. Answer A is wrong because Thr308 phosphorylation still enables some AKT function, so responses aren't completely lost. Answer C incorrectly suggests enhanced mTORC1 activity, but reduced AKT activation would actually decrease mTORC1 signaling. Answer D is partially correct about apoptotic sensitivity but wrong about glucose metabolism - Thr308 phosphorylation should maintain normal metabolic responses, and the phrasing suggests these are independent when they're both AKT-dependent. Remember: AKT's dual phosphorylation sites have overlapping but distinct roles. Questions testing site-specific mutations often focus on which functions remain versus which are lost.

Question 2

Researchers studying cellular stress responses discover that when cells are subjected to oxidative stress, FOXO transcription factors translocate to the nucleus despite continued growth factor signaling and PI3K activation. Which aspect of the pathway is most likely compromised under these conditions?

  1. Growth factor receptor autophosphorylation is inhibited by reactive oxygen species
  2. PI3K lipid kinase activity is directly inactivated by oxidative damage
  3. AKT kinase activity is reduced by oxidative modifications of critical residues (correct answer)
  4. FOXO proteins become resistant to AKT-mediated phosphorylation under stress
  5. mTORC2 complex assembly is disrupted by oxidative stress conditions
Explanation: When you encounter questions about transcription factor regulation under stress conditions, focus on how cellular stress can disrupt normal signaling cascades at specific molecular targets. Under normal conditions, the PI3K/AKT pathway keeps FOXO transcription factors in the cytoplasm through AKT-mediated phosphorylation. Since the question states that growth factor signaling and PI3K remain active during oxidative stress, yet FOXO still translocates to the nucleus, the disruption must occur downstream of PI3K. AKT is particularly vulnerable to oxidative stress because reactive oxygen species can modify critical cysteine and methionine residues in its kinase domain, reducing its catalytic activity. This impaired AKT function means FOXO proteins aren't adequately phosphorylated and thus migrate to the nucleus to activate stress response genes. Option A is incorrect because the question explicitly states that growth factor signaling continues, indicating receptor function remains intact. Option B is wrong since PI3K activation is specifically mentioned as ongoing, ruling out direct PI3K inactivation. Option D incorrectly suggests FOXO becomes resistant to phosphorylation, but the real issue is that AKT can't effectively phosphorylate FOXO due to its own oxidative damage. Remember that oxidative stress questions often test your understanding of which pathway components are most susceptible to reactive oxygen species. AKT's sensitivity to oxidative modifications makes it a common bottleneck where normal growth signals fail to suppress stress responses, allowing cells to activate protective transcriptional programs even when growth conditions appear favorable.

Question 3

In an experimental system, researchers can independently control PI3K and mTORC1 activity. They find that activating PI3K alone promotes cell survival but not growth, while activating mTORC1 alone promotes growth but not survival. However, activating both together produces a synergistic increase in cell proliferation. What best explains this synergy?

  1. PI3K and mTORC1 directly phosphorylate each other to enhance their activities
  2. Survival signaling allows cells to live long enough to benefit from growth signaling (correct answer)
  3. mTORC1 requires PIP3 as a direct cofactor for its kinase activity
  4. PI3K activation prevents the negative feedback from mTORC1 to insulin signaling
  5. Both pathways are required to overcome cell cycle checkpoints simultaneously
Explanation: This question tests your understanding of how cell survival and growth pathways work together to drive cell proliferation. When you encounter questions about pathway interactions, think about whether the effects are direct biochemical interactions or functional relationships. The key insight here is that cell proliferation requires both survival signals (to prevent cell death) and growth signals (to increase cell mass and prepare for division). PI3K activation promotes survival primarily through AKT, which phosphorylates and inactivates pro-apoptotic proteins like BAD and FoxO transcription factors. mTORC1 activation drives anabolic processes like protein synthesis and lipid biosynthesis, increasing cell mass. However, growth without survival signals leaves cells vulnerable to apoptosis, while survival without growth fails to prepare cells for division. When both pathways are active simultaneously, cells can both stay alive AND accumulate the biomass needed for successful proliferation - creating synergy. Answer A is incorrect because PI3K and mTORC1 don't directly phosphorylate each other, though PI3K does activate mTORC1 indirectly through AKT. Answer C is wrong because mTORC1's kinase activity doesn't require PIP3 as a direct cofactor - PIP3 acts upstream through AKT signaling. Answer D misrepresents the relationship; while mTORC1 does create negative feedback to insulin signaling through S6K1, this isn't the primary explanation for the observed synergy. Remember that pathway "synergy" often reflects functional complementarity rather than direct biochemical interactions - survival and growth pathways address different cellular needs that must both be satisfied for proliferation.

Question 4

A pharmaceutical company tests a drug that specifically prevents the interaction between TSC1 and TSC2 without affecting either protein's individual stability or expression. In cancer cells treated with this drug, which outcome would be most predicted?

  1. Increased autophagy due to enhanced energy sensing
  2. Enhanced apoptosis through mTORC1-independent mechanisms
  3. Hyperactivation of mTORC1 leading to increased protein synthesis (correct answer)
  4. Reduced AKT activity due to loss of upstream regulation
  5. Cell cycle arrest in G1 phase due to inadequate growth signals
Explanation: When you encounter questions about the TSC1/TSC2 complex, remember this pathway controls cell growth through mTORC1 regulation. TSC1 and TSC2 work together as a functional unit - TSC1 stabilizes TSC2, while TSC2 provides the catalytic activity that inhibits mTORC1 by converting Rheb-GTP to its inactive GDP form. If a drug prevents TSC1-TSC2 interaction, you're essentially breaking apart this growth-suppressing complex. Without TSC1, TSC2 becomes unstable and non-functional, even though the individual proteins remain present. This removes the "brakes" on mTORC1, allowing Rheb-GTP to accumulate and hyperactivate mTORC1. The result is dramatically increased protein synthesis, cell growth, and proliferation - exactly what cancer cells thrive on. Looking at the wrong answers: (A) suggests increased autophagy, but mTORC1 hyperactivation actually suppresses autophagy since the cell thinks nutrients are abundant. (B) mentions enhanced apoptosis through mTORC1-independent mechanisms, but this drug's primary effect works directly through the mTORC1 pathway, and hyperactive mTORC1 typically promotes survival, not death. (D) proposes reduced AKT activity, but AKT operates upstream of TSC1/TSC2 - disrupting the TSC complex wouldn't directly affect AKT levels. For cell biology exams, always trace signaling pathways step-by-step. When a regulatory complex is disrupted, ask yourself: "What normally gets inhibited?" Then predict the opposite effect when that inhibition is removed.

Question 5

Researchers studying cancer metabolism observe that tumor cells maintain high mTORC1 activity even during glucose starvation, unlike normal cells which show mTORC1 inhibition. Analysis reveals that these cancer cells have lost AMPK function. Which downstream effect would most directly explain the continued mTORC1 activity?

  1. Inability to phosphorylate and activate TSC2 during energy stress (correct answer)
  2. Loss of direct AMPK-mediated inhibitory phosphorylation of mTOR
  3. Failure to suppress PI3K activity through AMPK-mediated feedback
  4. Reduced autophagy leading to accumulation of mTORC1 activators
  5. Enhanced glycolysis maintaining ATP levels despite glucose starvation
Explanation: When you encounter questions about mTORC1 regulation during metabolic stress, focus on the key regulatory pathway: AMPK → TSC2 → mTORC1. This is the primary mechanism by which cells sense energy status and adjust growth signaling accordingly. During glucose starvation, normal cells activate AMPK, which then phosphorylates TSC2 (tuberous sclerosis complex 2). This phosphorylation activates TSC2's GTPase-activating protein (GAP) function, causing it to convert Rheb-GTP to Rheb-GDP. Since mTORC1 requires Rheb-GTP for activation, this effectively shuts down mTORC1 during energy stress. In cancer cells lacking AMPK function, this critical checkpoint is lost—TSC2 cannot be properly activated, Rheb remains in its GTP-bound state, and mTORC1 stays active even when it shouldn't. This directly explains why answer A is correct. Answer B is incorrect because AMPK doesn't directly phosphorylate mTOR itself; it works through the TSC1/TSC2 complex and Rheb. Answer C misidentifies the pathway—while AMPK can influence PI3K signaling, this isn't the direct mechanism for mTORC1 regulation during acute energy stress. Answer D confuses cause and effect; reduced autophagy is a consequence of continued mTORC1 activity, not the mechanism explaining why mTORC1 remains active. Remember this hierarchy: AMPK → TSC2 → Rheb → mTORC1. Most mTORC1 regulation questions on cell biology exams test your understanding of this central energy-sensing pathway and where it can go wrong in disease states.

Question 6

A researcher observes that when PI3K activity is pharmacologically inhibited in cultured fibroblasts, the cells continue to proliferate normally for several hours before growth arrest occurs. However, when the same cells are treated with an AKT inhibitor, growth arrest occurs within 30 minutes. What is the most likely explanation for this difference in timing?

  1. PI3K has multiple downstream targets besides AKT that can maintain short-term growth signaling
  2. AKT protein has a much shorter half-life than PI3K protein in these cells
  3. PI3K inhibition takes longer to deplete existing PIP3 pools compared to direct AKT inhibition (correct answer)
  4. AKT functions independently of PI3K in growth control pathways
  5. PI3K inhibitors have lower binding affinity than AKT inhibitors in this cell type
Explanation: When you encounter questions about signaling pathway kinetics, think about the difference between depleting existing signaling molecules versus blocking protein function directly. The timing difference reveals how these inhibitors work mechanistically. PI3K produces PIP₃ (phosphatidylinositol 3,4,5-trisphosphate), which then recruits and activates AKT at the plasma membrane. When PI3K is inhibited, existing PIP₃ molecules remain in the membrane and continue activating AKT until they're gradually degraded by phosphatases like PTEN. This depletion process takes several hours, explaining why growth arrest is delayed. In contrast, directly inhibiting AKT immediately blocks its kinase activity regardless of PIP₃ levels, causing rapid growth arrest within 30 minutes. Option A is incorrect because while PI3K does have other downstream targets (like PDK1 and SGK), the question specifically compares timing differences, not alternative pathways. Option B misses the point entirely—protein half-lives don't explain the functional timing difference observed here. The inhibitors block enzyme activity, not protein degradation. Option D contradicts established cell biology; AKT is fundamentally dependent on PI3K-generated PIP₃ for its membrane recruitment and activation. Study tip: Remember that upstream inhibitors often show delayed effects because existing downstream signaling molecules must be depleted first, while direct target inhibition shows immediate effects. This principle applies broadly to signaling cascades and helps predict experimental outcomes in cell biology.

Question 7

In a cell line with constitutively active PI3K, researchers find that mTORC1 activity remains low despite high AKT phosphorylation. Further investigation reveals elevated AMPK activity due to glucose deprivation. Which mechanism best explains why mTORC1 remains inactive?

  1. AMPK directly phosphorylates and inhibits AKT upstream of mTORC1 activation
  2. AMPK phosphorylates TSC2, enhancing its GAP activity toward Rheb-GTP (correct answer)
  3. Glucose deprivation prevents PI3K from generating sufficient PIP3 levels
  4. AMPK competes with AKT for binding to the same regulatory sites on mTOR
  5. Energy stress causes mTORC1 to dissociate into inactive mTOR subunits
Explanation: When you encounter questions about mTORC1 regulation, focus on the key signaling nodes where multiple pathways converge. The mTORC1 pathway integrates growth signals (PI3K/AKT) with energy status (AMPK), and understanding how these pathways interact is crucial. Under energy stress conditions like glucose deprivation, AMPK acts as the cell's energy sensor and overrides growth signals to preserve cellular resources. Despite constitutively active PI3K and high AKT phosphorylation (indicating strong growth signals), mTORC1 remains inactive because AMPK phosphorylates TSC2 (tuberous sclerosis complex 2) at specific serine residues. This phosphorylation enhances TSC2's GTPase-activating protein (GAP) activity, which converts active Rheb-GTP to inactive Rheb-GDP. Since Rheb-GTP is required for mTORC1 activation, this mechanism effectively shuts down mTORC1 regardless of upstream AKT activity. Option A is incorrect because AMPK doesn't directly inhibit AKT; both kinases can be simultaneously active. Option C misses the point—the question states PI3K is constitutively active, so PIP3 levels aren't the limiting factor. Option D is wrong because AMPK and AKT don't compete for the same binding sites on mTOR; they regulate mTORC1 through distinct upstream mechanisms. Remember this hierarchy: energy status (AMPK) trumps growth signals (AKT) in mTORC1 regulation. AMPK's phosphorylation of TSC2 is the critical checkpoint that allows energy stress to override growth signals, making TSC2 the key integration point for these opposing cellular demands.

Question 8

A cancer cell line shows resistance to apoptosis despite DNA damage. Analysis reveals normal p53 activation and BAD protein expression, but BAD remains sequestered by 14-3-3 proteins even under stress conditions. Which component of the PI3K/AKT pathway is most likely hyperactivated in these cells?

  1. PI3K catalytic subunit leading to excessive PIP3 production
  2. AKT kinase activity resulting in persistent BAD phosphorylation (correct answer)
  3. mTORC2 complex enhancing AKT membrane recruitment
  4. PDK1 kinase causing constitutive AKT activation at Thr308
  5. mTORC1 complex promoting survival through S6K1 activation
Explanation: When you encounter apoptosis resistance questions, focus on the key regulatory checkpoints that control cell death pathways. Here, the critical clue is that BAD remains sequestered by 14-3-3 proteins despite stress conditions, which points to dysregulated phosphorylation control. BAD is a pro-apoptotic protein that normally promotes cell death when dephosphorylated. However, when AKT phosphorylates BAD at specific serine residues, phosphorylated BAD gets sequestered by 14-3-3 proteins and cannot trigger apoptosis. Since BAD stays sequestered even under DNA damage stress (when it should be released), this indicates hyperactive AKT kinase is continuously phosphorylating BAD. This persistent phosphorylation prevents the normal apoptotic response, explaining the cancer cell's resistance to death signals. Answer B correctly identifies AKT hyperactivation as the culprit. Answer A is incorrect because while excessive PIP3 could activate AKT, the question specifically points to the downstream effect on BAD phosphorylation, making AKT the more direct answer. Answer C misses the mark because mTORC2, though it activates AKT, operates through different mechanisms and timeframes than the immediate BAD phosphorylation described. Answer D focuses on PDK1 and Thr308 phosphorylation, but this represents AKT activation rather than the sustained kinase activity needed for continuous BAD sequestration. Remember: When analyzing apoptosis resistance, trace the pathway from the observed phenotype backward. If pro-apoptotic proteins are inappropriately sequestered, look for hyperactive survival kinases like AKT that phosphorylate and inactivate these death signals.

Question 9

Researchers studying autophagy regulation find that amino acid withdrawal normally induces autophagy, but in their experimental cells, autophagy fails to occur despite amino acid starvation. They discover that Rheb-GTP levels remain high. Which protein is most likely defective in these cells?

  1. TSC1, preventing proper TSC1/TSC2 complex formation (correct answer)
  2. ULK1, blocking the initiation of autophagosome formation
  3. PTEN, causing excessive PIP3 accumulation
  4. S6K1, failing to provide negative feedback to insulin signaling
  5. Raptor, preventing mTORC1 assembly and substrate recognition
Explanation: When you encounter autophagy questions, focus on the mTOR pathway's central role in nutrient sensing and autophagy regulation. Autophagy normally activates during nutrient starvation when mTOR is inhibited, but here it's failing despite amino acid withdrawal. The key clue is that Rheb-GTP levels remain high. Rheb (Ras homolog enriched in brain) is a small GTPase that directly activates mTOR when bound to GTP. For autophagy to proceed normally, Rheb must be inactivated by converting it from the GTP-bound (active) state to the GDP-bound (inactive) state. This conversion is catalyzed by the TSC1/TSC2 complex, which acts as a GTPase-activating protein (GAP) for Rheb. Answer A is correct because if TSC1 is defective, the TSC1/TSC2 complex cannot form properly or function effectively. Without functional TSC1/TSC2, Rheb remains in its active GTP-bound state, continuously activating mTOR even during starvation. This prevents autophagy induction despite the absence of amino acids. Answer B is wrong because ULK1 acts downstream of mTOR - if mTOR is inappropriately active (due to high Rheb-GTP), ULK1 would be phosphorylated and inhibited, but ULK1 itself isn't the primary defect. Answer C is incorrect because PTEN regulates PI3K/Akt signaling upstream of TSC1/TSC2, but wouldn't directly explain persistently high Rheb-GTP levels. Answer D is wrong because S6K1 defects affect feedback regulation but wouldn't prevent Rheb inactivation. Remember: High Rheb-GTP during starvation immediately points to TSC1/TSC2 complex dysfunction as the primary defect.

Question 10

In neurons, insulin-like growth factor (IGF-1) treatment promotes both survival and growth. However, when researchers selectively inhibit mTORC2 while leaving mTORC1 intact, they observe that IGF-1 still promotes growth but loses its survival effect. What is the most likely explanation?

  1. mTORC2 is required for IGF-1 receptor autophosphorylation and signal initiation
  2. mTORC2-mediated AKT phosphorylation at Ser473 is specifically required for survival signaling (correct answer)
  3. mTORC1 and mTORC2 have redundant functions in growth but not survival pathways
  4. mTORC2 directly phosphorylates pro-apoptotic proteins independently of AKT
  5. Growth signaling requires both mTOR complexes while survival requires only mTORC1
Explanation: When you encounter questions about mTOR complexes and growth factor signaling, focus on the distinct roles of mTORC1 and mTORC2, particularly in how they differentially regulate AKT signaling pathways. IGF-1 activates AKT through a two-step phosphorylation process. PDK1 phosphorylates AKT at Thr308, while mTORC2 phosphorylates AKT at Ser473. This dual phosphorylation creates fully active AKT, but critically, these phosphorylation sites have different functional consequences. The Ser473 phosphorylation by mTORC2 is specifically crucial for AKT's anti-apoptotic functions, including phosphorylation of pro-survival targets like BAD and FoxO transcription factors. When mTORC2 is inhibited, AKT retains some activity from Thr308 phosphorylation, allowing growth signaling to continue, but loses the Ser473-dependent survival signaling. Answer A is incorrect because IGF-1 receptor autophosphorylation occurs upstream of mTOR complexes and doesn't require mTORC2. Answer C misrepresents the relationship—mTORC1 and mTORC2 have distinct, not redundant functions. Answer D is wrong because mTORC2's primary role in survival is through AKT activation, not direct phosphorylation of apoptotic proteins. The correct answer is B: mTORC2-mediated AKT phosphorylation at Ser473 is specifically required for survival signaling. Study tip: Remember that mTORC2's unique contribution is the Ser473 phosphorylation of AKT, which is essential for anti-apoptotic signaling. This distinction between growth and survival functions of AKT is a common exam concept.

Question 11

A pharmaceutical company develops a novel cancer therapy that specifically targets the PH domain of AKT. In cell culture studies, this treatment effectively reduces tumor cell survival, but surprisingly, it has minimal impact on tumor cell growth rates. Which aspect of AKT function is most likely being selectively disrupted?

  1. AKT's ability to phosphorylate mTORC1 components for growth signaling
  2. AKT's membrane localization and subsequent activation by PDK1 and mTORC2 (correct answer)
  3. AKT's kinase domain activity toward all downstream substrates equally
  4. AKT's interaction with growth factor receptors at the plasma membrane
  5. AKT's nuclear translocation required for transcriptional regulation
Explanation: When you encounter questions about targeted cancer therapies, focus on how disrupting specific protein domains affects distinct cellular functions. The PH domain of AKT is crucial for membrane recruitment and activation, not enzymatic activity itself. The correct answer is B because the PH domain specifically binds PIP₃ at the plasma membrane, allowing AKT to be positioned where PDK1 and mTORC2 can phosphorylate and fully activate it. By targeting this domain, the drug prevents proper membrane localization and subsequent activation, which explains why survival decreases (AKT can't promote anti-apoptotic signals) while growth rates remain largely unchanged (some AKT-independent growth pathways may compensate). Choice A is incorrect because mTORC1 phosphorylation by AKT primarily drives growth and proliferation. If this were disrupted, you'd expect reduced growth rates, contradicting the observation. Choice C misunderstands the mechanism—targeting the PH domain doesn't directly affect kinase activity; it prevents activation altogether, making this explanation too broad and mechanistically wrong. Choice D is incorrect because AKT doesn't directly interact with growth factor receptors. Instead, it responds downstream after PIP₃ generation by activated PI3K. The key insight is that different protein domains have specialized functions. Remember that the PH domain is like AKT's "address label" for membrane localization, while the kinase domain is its "toolbox" for phosphorylating substrates. Disrupting localization prevents activation without directly affecting catalytic capability, creating selective functional deficits.

Question 12

Researchers observe that in liver cells, insulin treatment rapidly activates mTORC1, but this activation is transient and returns to baseline within 2 hours despite continued insulin presence. Phosphorylation analysis shows that AKT remains active throughout the treatment. What mechanism most likely explains this pattern?

  1. Insulin receptor internalization and degradation reduces upstream signaling
  2. S6K1-mediated negative feedback phosphorylation of insulin receptor substrates (correct answer)
  3. PTEN activation leads to PIP3 depletion and pathway shutdown
  4. mTORC1 substrate depletion causes apparent activity reduction
  5. TSC2 phosphorylation by AKT becomes saturated over time
Explanation: When you encounter questions about insulin signaling and mTORC1 activation patterns, focus on the feedback mechanisms that regulate these pathways. The key insight here is understanding how cells prevent excessive growth signaling through built-in negative feedback loops. The transient mTORC1 activation despite sustained insulin presence and continued AKT activity points to S6K1-mediated negative feedback. When mTORC1 is activated, it phosphorylates S6K1, which then phosphorylates insulin receptor substrates (IRS proteins) on serine residues. This phosphorylation reduces IRS protein function and promotes their degradation, effectively dampening the insulin signal reaching mTORC1. This creates a self-limiting system where mTORC1 activation triggers its own downregulation. Answer A is incorrect because insulin receptor internalization would affect AKT activity, but the question states AKT remains active throughout treatment. Answer C misrepresents the pathway - PTEN activation would reduce AKT activity, contradicting the observed sustained AKT phosphorylation. Answer D suggests substrate depletion causes apparent reduced activity, but this doesn't explain the specific temporal pattern or why the effect is transient rather than progressive. The correct answer is B because S6K1 negative feedback specifically explains how mTORC1 can be downregulated while AKT remains active - the feedback occurs downstream of AKT but upstream of mTORC1 reactivation. Remember this pattern: in growth factor signaling questions, when you see sustained upstream activity but transient downstream effects, look for negative feedback loops as the regulatory mechanism.

Question 13

In a cell-free biochemical assay, researchers add purified AKT, its known substrates, and ATP to measure kinase activity. They observe robust phosphorylation of GSK3β but minimal phosphorylation of FOXO proteins, even though both substrates are present at saturating concentrations. What is the most likely explanation?

  1. FOXO proteins require additional cofactors not present in the cell-free system
  2. The AKT preparation lacks the proper subcellular localization signals
  3. GSK3β has higher binding affinity for AKT than FOXO proteins under these conditions
  4. FOXO phosphorylation requires prior phosphorylation of AKT at both Thr308 and Ser473 (correct answer)
  5. The assay conditions favor metabolic substrates over transcriptional substrates
Explanation: When you encounter questions about kinase activity in cell-free systems, focus on the regulatory mechanisms that control enzyme function. AKT is a central signaling kinase, but its activity depends critically on proper activation through phosphorylation. AKT requires dual phosphorylation for full catalytic activity: phosphorylation at Thr308 (by PDK1) and Ser473 (by mTORC2). Without both modifications, AKT exhibits only partial activity. Importantly, different substrates have varying sensitivity to AKT's activation state. GSK3β can be phosphorylated by partially active AKT, while FOXO proteins require fully activated AKT with both phosphorylation sites occupied. This explains why you see robust GSK3β phosphorylation but minimal FOXO phosphorylation in the cell-free assay. Choice A is incorrect because FOXO proteins don't require additional cofactors beyond those needed for basic kinase activity (ATP, Mg²⁺). Choice B misses the point—subcellular localization isn't relevant in a cell-free system where all components are mixed together. Choice C suggests differential binding affinity, but both substrates are at saturating concentrations, meaning binding shouldn't be limiting. The correct answer is D because FOXO phosphorylation specifically requires AKT that has been fully activated through dual phosphorylation. If the purified AKT preparation lacks complete activation, it would show this exact pattern of substrate selectivity. Remember: AKT substrate specificity changes with activation state. Always consider whether kinases in experimental systems have undergone their required regulatory modifications.

Question 14

A research group creates a cell line where mTORC1 can be rapidly and reversibly inhibited by a small molecule. When they inhibit mTORC1 in actively growing cells, they observe that protein synthesis drops immediately, but autophagy induction is delayed by several hours. What mechanism most likely accounts for this delay in autophagy activation?

  1. ULK1 protein must be newly synthesized before autophagy can begin
  2. Existing ULK1 inhibitory phosphorylations must be removed by phosphatases (correct answer)
  3. Autophagosome formation requires degradation of growth-promoting proteins first
  4. AMPK activation is required and occurs slowly in response to mTORC1 inhibition
  5. Autophagy genes must be transcriptionally activated before the process can begin
Explanation: When you encounter questions about mTORC1 and autophagy regulation, focus on the phosphorylation-based control mechanisms that govern this pathway. mTORC1 actively suppresses autophagy by phosphorylating ULK1 (a key autophagy initiator) at specific inhibitory sites, keeping it inactive even when the protein is present. The delay in autophagy activation after mTORC1 inhibition occurs because existing ULK1 proteins are already heavily phosphorylated at inhibitory sites. Even though mTORC1 can no longer add new phosphorylations, the existing ones must be actively removed by phosphatases before ULK1 can become functional. This dephosphorylation process takes time - several hours - explaining why autophagy induction is delayed compared to the immediate drop in protein synthesis. Answer B correctly identifies this phosphatase-dependent mechanism. Answer A is incorrect because ULK1 protein is already present in cells; new synthesis isn't required for autophagy initiation. Answer C misrepresents the process - autophagy doesn't require prior degradation of growth-promoting proteins, and autophagosome formation can begin once ULK1 is activated. Answer D incorrectly suggests AMPK activation is the rate-limiting step. While AMPK does promote autophagy, it's not the primary cause of the delay described here. Remember that mTORC1's control over cellular processes often involves phosphorylation switches. When you see questions about delays in pathway activation after mTORC1 inhibition, consider whether existing inhibitory phosphorylations need to be removed rather than assuming new protein synthesis is required.

Question 15

Researchers studying tissue regeneration find that stem cells require PI3K/AKT signaling for survival but must downregulate mTORC1 to maintain their undifferentiated state. They develop a strategy to selectively inhibit mTORC1 while maintaining AKT activity. Which approach would be most effective?

  1. Overexpressing PTEN to reduce overall pathway activity
  2. Using rapamycin to specifically target mTORC1 function
  3. Inhibiting PI3K while supplementing with constitutively active AKT
  4. Overexpressing TSC1/TSC2 complex to enhance Rheb GAP activity (correct answer)
  5. Depleting amino acids to reduce mTORC1 activation naturally
Explanation: When you encounter questions about pathway regulation, focus on understanding how different components interact within the signaling cascade and where selective intervention is possible. The PI3K/AKT/mTOR pathway operates hierarchically: PI3K activates AKT, which then activates mTORC1 through multiple mechanisms, including inhibition of the TSC1/TSC2 complex. The challenge here is maintaining AKT's pro-survival signaling while blocking mTORC1's differentiation-promoting effects. Option D works because TSC1/TSC2 acts as a GAP (GTPase-activating protein) for Rheb, converting active Rheb-GTP to inactive Rheb-GDP. Since Rheb-GTP directly activates mTORC1, overexpressing TSC1/TSC2 effectively shuts down mTORC1 while leaving upstream AKT signaling intact. This creates the precise selective inhibition needed. Option A fails because PTEN overexpression would reduce PI3K signaling globally, eliminating the AKT survival signals the stem cells require. Option B is problematic because while rapamycin does inhibit mTORC1, it can also disrupt mTORC2 with prolonged treatment, and mTORC2 is needed for full AKT activation. Option C is impractical and risky—simultaneously inhibiting PI3K while trying to maintain constitutive AKT activity would be technically challenging and potentially create off-target effects. For pathway questions, always map out the signaling cascade and identify intervention points that achieve the desired selectivity. Understanding where feedback loops and cross-regulation occur will help you recognize which manipulations preserve essential functions while blocking unwanted ones.

Question 16

In cardiac muscle cells under ischemic conditions, researchers observe that AKT becomes hyperphosphorylated at Ser473 but shows reduced kinase activity toward its substrates. Further analysis reveals elevated protein phosphatase 2A (PP2A) activity. Which mechanism best explains this apparent paradox?

  1. PP2A dephosphorylates AKT substrates faster than AKT can phosphorylate them
  2. Ischemia causes AKT protein misfolding despite maintained phosphorylation
  3. PP2A dephosphorylates Thr308 while Ser473 phosphorylation is maintained (correct answer)
  4. Hyperphosphorylation at Ser473 actually inhibits rather than activates AKT
  5. PP2A competes with AKT for binding to the same substrate proteins
Explanation: When you encounter questions about protein kinase regulation, remember that full activation typically requires multiple phosphorylation events at specific sites. AKT (protein kinase B) is a classic example requiring phosphorylation at both Thr308 and Ser473 for optimal kinase activity. The key to solving this paradox lies in understanding AKT's dual phosphorylation requirement. While Ser473 remains hyperphosphorylated, PP2A is selectively dephosphorylating Thr308, which is essential for AKT's catalytic activity. This creates a situation where one activating phosphorylation site is maintained while the other is removed, resulting in reduced kinase function despite apparent "activation" at Ser473. Option A incorrectly suggests PP2A acts on AKT substrates rather than AKT itself. The question states AKT has reduced activity toward substrates, not that substrates are being dephosphorylated faster than phosphorylated. Option B proposes protein misfolding, but there's no evidence for this mechanism. The maintained Ser473 phosphorylation suggests the protein structure remains intact enough for this modification. Option D misinterprets Ser473's role entirely. Ser473 phosphorylation is consistently activating for AKT - it doesn't switch to an inhibitory function under ischemic conditions. For cell biology exams, remember that multi-site phosphorylation often creates regulatory complexity. When you see apparent contradictions in kinase activity versus phosphorylation status, consider whether different phosphorylation sites are being differentially regulated rather than assuming simple on/off switches.

Question 17

Researchers investigating drug resistance in cancer cells discover that resistant cells maintain high AKT activity even when treated with PI3K inhibitors. Genetic analysis reveals amplification of PDK1 and loss of PHLPP phosphatase. Which aspect of AKT regulation allows for this PI3K-independent activation?

  1. PDK1 can phosphorylate AKT at Thr308 independently of PIP3 when overexpressed
  2. Loss of PHLPP removes inhibitory phosphorylations that normally suppress AKT
  3. AKT can autophosphorylate when PDK1 levels exceed normal cellular concentrations
  4. PHLPP loss prevents dephosphorylation while PDK1 amplification enhances phosphorylation (correct answer)
  5. PDK1 overexpression compensates for reduced PIP3 by increasing kinase efficiency
Explanation: When you encounter questions about drug resistance and signaling pathways, focus on how multiple regulatory mechanisms work together to control protein activity. The AKT pathway is controlled by both phosphorylation (activation) and dephosphorylation (inactivation) events. AKT activation requires phosphorylation at two key sites: Thr308 (by PDK1) and Ser473 (by mTORC2). While PDK1 normally requires PIP3 for full activity, the phosphatase PHLPP actively removes these phosphate groups to keep AKT activity in check. In these resistant cancer cells, you have a "perfect storm" - amplified PDK1 increases the phosphorylation rate while lost PHLPP eliminates the dephosphorylation that would normally turn AKT off. This combination maintains high AKT activity even without PI3K. Answer D correctly identifies both mechanisms working together: PDK1 amplification drives phosphorylation while PHLPP loss prevents the removal of those phosphates. Answer A is incorrect because PDK1 still typically requires some PIP3 or membrane localization signals - it doesn't become completely PIP3-independent just from overexpression. Answer B only addresses half the story (removing inhibition) but ignores the enhanced phosphorylation from PDK1 amplification. Answer C is wrong because AKT cannot autophosphorylate at its regulatory sites - it requires other kinases like PDK1 and mTORC2. For pathway questions, always consider both the "gas pedal" (activating mechanisms) and "brakes" (inhibitory mechanisms). Drug resistance often involves pushing the accelerator while cutting the brake lines simultaneously.

Question 18

In a study of aging, researchers find that aged muscle cells show reduced response to insulin-like growth factor despite normal receptor expression and PI3K activation. However, these cells respond normally to direct mTORC1 activators. Proteomic analysis reveals increased levels of inhibitory kinases that target the pathway. Which protein is most likely hyperactivated in these aged cells?

  1. GSK3β, which inhibits protein synthesis through eIF2B phosphorylation
  2. S6K1, which creates negative feedback to insulin receptor substrates
  3. AMPK, which phosphorylates TSC2 and directly inhibits mTORC1
  4. JNK, which phosphorylates IRS-1 on inhibitory serine residues (correct answer)
  5. p38 MAPK, which competes with AKT for substrate binding
Explanation: When you encounter questions about insulin signaling defects in aging, focus on where the pathway is disrupted versus where it remains functional. This question describes cells with normal early signaling (receptor expression, PI3K activation) but impaired overall response, plus normal response to direct mTORC1 activation - this pattern points to a problem in the middle of the pathway. The key insight is that JNK (c-Jun N-terminal kinase) becomes hyperactivated during aging and cellular stress. JNK phosphorylates IRS-1 (insulin receptor substrate-1) on inhibitory serine residues, which prevents IRS-1 from properly transmitting the insulin signal downstream. This explains why the cells show reduced IGF response despite normal receptor expression and PI3K activation - the signal is being blocked at the IRS-1 level. Since direct mTORC1 activators bypass this upstream blockade, they still work normally. Looking at the wrong answers: (A) GSK3β doesn't directly inhibit eIF2B through phosphorylation in this context, and it would be downstream of the observed defect. (B) S6K1 negative feedback would affect the pathway differently and wouldn't explain the specific pattern described. (C) AMPK activation would directly inhibit mTORC1, contradicting the observation that direct mTORC1 activators still work. Remember that aging-related insulin resistance often involves inflammatory kinases like JNK creating serine phosphorylation-mediated inhibition of IRS proteins. When you see preserved downstream function but impaired upstream signaling, look for inhibitory modifications at the receptor substrate level.

Question 19

In a study of metabolic regulation, researchers find that muscle cells treated with a specific inhibitor show reduced glucose uptake despite normal insulin receptor activation and PI3K activity. AKT phosphorylation at Thr308 is normal, but Ser473 phosphorylation is abolished. Which complex is most likely targeted by this inhibitor?

  1. mTORC1, which regulates glucose transporter expression
  2. mTORC2, which phosphorylates AKT at Ser473 (correct answer)
  3. PDK1 complex, which phosphorylates AKT at Thr308
  4. PI3K complex, which generates PIP3 for AKT activation
  5. TSC1/TSC2 complex, which regulates mTOR activity
Explanation: When you encounter questions about AKT signaling and glucose metabolism, focus on the dual phosphorylation requirement for full AKT activation. AKT needs phosphorylation at both Thr308 and Ser473 to achieve maximum activity and properly regulate downstream targets like glucose transporters. The key clue here is that Thr308 phosphorylation remains normal while Ser473 phosphorylation is completely abolished, yet insulin receptor and PI3K activity are intact. This specific pattern points directly to mTORC2 dysfunction. mTORC2 (mechanistic target of rapamycin complex 2) is the primary kinase responsible for phosphorylating AKT at Ser473. Without this phosphorylation, AKT cannot fully activate glucose uptake mechanisms, explaining the reduced glucose uptake despite normal upstream signaling. Looking at the incorrect options: A) mTORC1 primarily regulates protein synthesis and cell growth downstream of AKT, not AKT phosphorylation itself. While it does influence glucose metabolism, it wouldn't cause this specific phosphorylation pattern. C) PDK1 complex phosphorylates AKT at Thr308, but the question states this phosphorylation is normal, ruling out PDK1 as the target. D) PI3K complex generates PIP3 and is explicitly stated to have normal activity, so it cannot be the inhibited target. Remember that AKT's dual phosphorylation sites have distinct kinases: PDK1 for Thr308 and mTORC2 for Ser473. When you see questions describing selective loss of one phosphorylation site, immediately consider which specific kinase is responsible for that site.

Question 20

A biotechnology company engineers cells to produce a modified growth factor that activates PI3K but not other receptor tyrosine kinase pathways. When they treat serum-starved cells with this factor, they observe AKT activation and cell survival, but no increase in cell size or protein synthesis. What component is most likely missing from this signaling scenario?

  1. Amino acid availability required for mTORC1 activation (correct answer)
  2. Adequate energy levels needed for anabolic processes
  3. Additional growth factor signals required for mTORC1 activation
  4. Proper mTORC2 assembly for complete AKT activation
  5. TSC1/TSC2 complex inactivation by AKT phosphorylation
Explanation: When you encounter questions about growth factor signaling and protein synthesis, focus on the mTORC1 pathway requirements. This pathway integrates multiple signals to control cell growth and anabolic processes. The scenario describes cells responding to PI3K/AKT activation with survival but lacking growth responses like increased size and protein synthesis. This pattern points to mTORC1 dysfunction, since mTORC1 specifically regulates protein synthesis, cell size, and anabolic metabolism downstream of growth factors. mTORC1 requires three key inputs: growth factor signaling (present via PI3K/AKT), energy sufficiency (ATP levels), and amino acid availability. The cells are serum-starved, meaning they lack the amino acids normally present in serum. Without amino acids, mTORC1 cannot activate even when growth factor and energy signals are adequate. This explains why you see AKT activation and survival (which depend on PI3K signaling) but no protein synthesis or cell growth (which require mTORC1). Looking at the wrong answers: (B) is incorrect because adequate energy would typically be present in cultured cells with glucose, and energy deficiency would likely impair AKT activation too. (C) is wrong since PI3K/AKT signaling alone is sufficient for mTORC1 activation when other requirements are met. (D) is incorrect because mTORC2 assembly issues would impair AKT activation itself, contradicting the observed AKT activity. Remember that mTORC1 acts as a cellular "coincidence detector" requiring simultaneous growth factors, energy, AND amino acids. Missing any one component blocks anabolic processes despite other signals being present.